Shots:

• The submission is based on P-III PSOARING 1 & PSOARING 2 data as well as interim results from PSOARING 3 long-term safety study evaluating the safety and efficacy of tapinarof vs vehicle in patients with plaque psoriasis
• Results: Improvement in PGA scores of 0 or 1 with a minimum 2-grade improvement from baseline @12 wks.- improvement in all 2EPs @ 12 wks.- 40% of patients achieved complete disease clearance with continued therapy. Additionally- remittive benefit of 4 mos. was identified following treatment discontinuation
• Tapinarof is a steroid-free- cosmetically elegant- topical cream for the treatment of PsO and AD

Ref: Businesswire | Image: Businesswire